CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 89 enrolled
Drug / intervention
donepezil HCL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02087865
NCT02087865Phase 4Completed
CompareCT.gov

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

The Cleveland Clinic·interventional·Posted Mar 14, 2014·Updated Aug 30, 2023

In Brief

A Phase 4 clinical trial evaluating donepezil HCL and Placebo for Genetic Risk for Alzheimer's Disease. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This study examines the sensitivity of functional MRI to detect brain changes caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for Alzheimer's Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenetic Risk for Alzheimer's Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 14, 2014
Enrollment StartMay 1, 2014
Primary CompletionDec 20, 2021
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 12.3 years ago

Interventions

donepezil HCLdrug

Placebodrug